News and Views

Nursing Considerations for Adverse Events From CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy offers options for pediatric patients with relapsed or refractory acute lymphoblastic leukemia, but it comes with a unique set of side effects that can range from mild to severe. As the primary patient providers, oncology nurses are often the first to identify signs and symptoms of adverse events and acute changes in patients’ status. Understanding what to watch for can improve outcomes and help nurses deliver safe, effective care.

Trending Topics

View All Topics

FDA Update

U.S. Food and Drug Administration (FDA)

FDA Grants Accelerated Approval to Avelumab for Urothelial Carcinoma

ONS member programs

ONS Cultivates New and Sustaining Member Programs Throughout the Seasons

Lung Cancer Screening

High-Risk Lung Cancer Screening Rates Remain Low

Darcy Burbage

Care Coordination

Creating and Sustaining Survivorship Care Plans in Practice

FDA Update

U.S. Food and Drug Administration (FDA)

FDA Approves Durvalumab for Urothelial Carcinoma Treatment

FDA Update

U.S. Food and Drug Administration (FDA)

FDA Grants Accelerated Approval to Brigatinib for ALK-Positive NSCLC

FDA Update

U.S. Food and Drug Administration (FDA)

FDA Approves Midostaurin for FLT3-Positive Adult AML, Advanced Systemic Mastocytosis

FDA Update

U.S. Food and Drug Administration (FDA)

FDA Expands Regorafenib Indications for Patients with HCC

Fraudulent Cancer Treatments

U.S. Food and Drug Administration (FDA)

FDA Issues Warnings to Fraudulent Cancer Treatment Companies

Early-Stage Melanoma

Disease Symptoms Most Likely to Predict Recurrence of Early-Stage Melanoma

Standards of Care

How Do I Move Standards of Care Into Practice?

What Are ONS’s Recommendations for Safe Handling of Hazardous Drugs?

What Are ONS’s Recommendations for Safe Handling of Hazardous Drugs?

Lori Brown Becomes ONS’s First Chief Experience Officer

Patient in Bed

Patients Treated for Early-Stage Breast Cancer Report Severe Side Effects

ONS Names Ellen Carr as Incoming CJON Editor

ONS Leaders Discuss Society’s Changing Role and Focus in Cancer Nursing Research

Immunotherapy Inquiry

The Case of the Immunotherapy Inquiry

FDA Update

U.S. Food and Drug Administration (FDA)

FDA Approves Marketing of First Digital Pathology Whole Slide Imaging System

FDA Update

U.S. Food and Drug Administration (FDA)

FDA Removes Risk Evaluation Management Strategies (REMS) for ESAs

Prostate Screening

Prostate Cancer

Revised USPSTF Draft Guidelines Recommend Individual Prostate Cancer Screening Decisions

Text Messaging

Secured Text Messaging Orders Declared Unacceptable by the Joint Commission

Nurses talking

Clinical Practice

AJCC Cancer Staging System Will See Changes in 2018

Bortezomib May Improve Outcomes in Multiple Myeloma

Multiple Myeloma

Bortezomib May Improve Outcomes in Multiple Myeloma

cancer research finds significant increase in survival rates

Annual Cancer Report Identifies Significant Increases in Survival

Immunotherapy Agents

What Oncology Nurses Need to Know About Immunotherapy Agents

Brenda Nevidjon

Serving on Boards Allows Nurses to Improve the Nation’s Health

FDA Update

U.S. Food and Drug Administration (FDA)

FDA Approves Marketing Ipsogen JAK2 RGQ PCR Kit to Help Evaluate Suspected Polycythemia Vera

Walking the dog

Cancer Prevention

Physical Activity Benefits Patients and Nurses Throughout Life

Mindfulness Meditation

Mindfulness Meditation Can Improve Safety in Your Practice

Colorectal Cancer Rates in Younger Adults

Cancer Research

Study Finds Increased Colorectal Cancer Rates in Younger Adults

Member Feedback

ONS’s 2017 Financial Priorities Are Based on Member Feedback

Heather Mackey

What Is ONS’s Process for Creating Oncology Nursing Competencies?

Nursing Competencies

Competencies Create Expert, Accountable Nurses Delivering Quality Care

FDA Update

U.S. Food and Drug Administration (FDA)

FDA Broadens Palbociclib Indication in Breast Cancer

FDA Update

U.S. Food and Drug Administration (FDA)

FDA Grants Regular Approval to Osimertinib for EGFR T790 Mutation-Positive NSCLC

Regina Cunningham

Oncology Nurse Appointed CEO of Hospital of the University of Pennsylvania

Nursing Education

ONS, ANA Partner Together for Healthy Nurse, Healthy Nation Campaign

HPV Vaccines Fight Against Oral Cancers and More

Clinical Practice

HPV Vaccines Fight Against Oral Cancers and More

FDA Approved Drugs

Recent FDA-Approved Drugs Offer More Options for NSCLC and Other Cancers

FDA Update

U.S. Food and Drug Administration (FDA)

FDA Approves Niraparib for Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

FDA Update

U.S. Food and Drug Administration (FDA)

FDA Approves Avelumab for Treatment of Patients With Metastatic Merkel Cell Carcinoma

Get Up Get Moving

Cancer Research

Physical Activity, Psychological Care Reduce Cancer-Related Fatigue

Oncology Nurse CE

Nursing Education

How Do I Apply My ILNA Points to My Learning Plan?

Antidepressant May Relieve Joint Pain From Aromatase Inhibitors

Symptom Management

Antidepressant May Relieve Joint Pain From Aromatase Inhibitors

HVO and ONS

ONS, HVO Partnership Offers International Opportunities for Nurses

Results from a new clinical trial have shown that the targeted therapy drug ibrutinib, a BTK inhibitor, can effectively treat graft-versus-host disease (GVHD), a common complication from allogeneic stem cell transplants. The study findings were reported at the American Society of Hematology’s 2016 annual meeting.

Cancer Research

Ibrutinib May Improve GVHD Symptoms

Biden speaks at South by Southwest in Austin, TX.

Cancer Moonshot

Biden Foundation to Continue Cancer Moonshot Work

Patient Resources

Leading Oncology Professional Societies Launch CancerLinQ® Ambassadors Program

Nurse on Computer

Clinical Practice

ONS and ASCO CancerLinQ Partnership Will Help Institutions Use Practice Data to Drive Greater Cancer Care

Back to Top ▲